A pooled analysis of the STEP 1-3 trials (n=2,117 semaglutide 2.4 mg, n=1,262 placebo) reported GI adverse events in 72.9% of the semaglutide group versus 47.1% of placebo, with nausea (43.9% vs 16.1%), diarrhea (29.7% vs 15.9%), vomiting (24.5% vs 6.3%), and constipation (24.2% vs 11.1%) the most common categories
IF has so many health benefits including reducing insulin resistance, lowers cholesterol, assists in weight loss, leads to increased mental focus and clarity, etc
A clinical events committee independently reviewed deaths to determine the cause
Vision changes: Individuals with diabetes should monitor for changes in eyesight, as blood sugar fluctuations can affect vision
On one hand, the product strives to support certain bodily functions, possibly assisting with stabilization and management
This way, youll have everything you need for administering your dose at the right time